KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Novavax (NVAX) Return on Sales (2016 - 2025)

Historic Return on Sales for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to 2.87%.

  • Novavax's Return on Sales fell 14400.0% to 2.87% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.34%, marking a year-over-year increase of 6600.0%. This contributed to the annual value of 0.27% for FY2024, which is 2800.0% up from last year.
  • Latest data reveals that Novavax reported Return on Sales of 2.87% as of Q3 2025, which was down 14400.0% from 0.61% recorded in Q2 2025.
  • Novavax's 5-year Return on Sales high stood at 0.78% for Q1 2025, and its period low was 3.81% during Q4 2021.
  • In the last 5 years, Novavax's Return on Sales had a median value of 0.7% in 2023 and averaged 1.07%.
  • Per our database at Business Quant, Novavax's Return on Sales soared by 71600bps in 2021 and then tumbled by -39200bps in 2023.
  • Quarter analysis of 5 years shows Novavax's Return on Sales stood at 3.81% in 2021, then surged by 87bps to 0.51% in 2022, then fell by -20bps to 0.61% in 2023, then tumbled by -50bps to 0.92% in 2024, then crashed by -213bps to 2.87% in 2025.
  • Its Return on Sales stands at 2.87% for Q3 2025, versus 0.61% for Q2 2025 and 0.78% for Q1 2025.